Type 2 Diabetes and Heart Disease

Type 2 Diabetes and Heart Disease

Aug 08, 2018 01:10 PM EDT - Author: Amber

 

If you have Type 2 Diabetes and are concerned about the health of your heart, this study could be for you. 

Those with diabetes know they are at a higher risk of having heart attacks, strokes, and other cardiovascular complications. If you've already had a stroke or a heart attack your chances are doubled for having another one. This study is seeking people who have type 2 diabetes to evaluate the effect of a new GLP-1 treatment, Efpeglenatide (similar to Victoza, Byetta, Trulicity, etc.). Efpeglenatide has been tested previously in approximately 720 humans and the results have shown a positive effect on glucose in the blood.

This study is approximately three years long.  All study visits are conducted locally in Salt Lake City, Utah.

Benefits of Participating:

  • Receive $50 per visit.
  • Study medications provided.
  • No cost to participate.
  • No insurance needed.
  • No change in your doctor.
  • Completely voluntary, no obligation to continue.

To Qualify, You Must:

  • Be age 18 or older.
  • Diagnosed with type 2 diabetes.
  • Have history of cardiovascular disease or risk factors

 

Please fill out the form below to be notified once this trial is open. By contacting us, you are in no  way obligated to participate.  All information submitted is kept strictly confidential and is never  shared or sold to third parties.

 

 


Get Involved!
First Name: *
Last Name: *
Email: *
Phone:
Age:
What studies would you be interested in participating in? (Select all that apply)

Arthritis

Diabetes Type 2

High Blood Pressure

Asthma

Gout

High Cholesterol

COPD/Emphysema

Heart Attack

Stroke

Diabetes Type 1

Heart Disease

Weight Loss

Acne

Migraine

Low Testosterone

Osteoarthritis

We’re always adding new studies to our list, what other conditions do you have or would you be interested in joining a study for? (I.E. Fibromyalgia, etc.)
Medications you currently take (Optional):
How Did You Hear About Us?

Subscribe to OCR's Monthly Newsletter
 
;